{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T11:52:15Z","timestamp":1773229935834,"version":"3.50.1"},"reference-count":45,"publisher":"American Medical Association (AMA)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Dermatol"],"published-print":{"date-parts":[[2025,3,1]]},"abstract":"Importance<\/jats:title>Cutaneous chronic graft-vs-host disease (GVHD) is independently associated with morbidity and mortality after allogeneic hematopoietic cell transplant. However, the health-related quality-of-life (HRQOL) domains that are most important to patients are poorly understood.<\/jats:p><\/jats:sec>Objective<\/jats:title>To perform a concept elicitation study to define HRQOL in cutaneous chronic GVHD from the patient perspective and to compare experiences of patients with epidermal vs sclerotic disease.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>A single-center qualitative analysis from open-ended, semistructured interviews and free-listing terms conducted between April and September 2023. Participants were 18 years or older with a diagnosis of active cutaneous chronic GVHD, purposefully sampled for epidermal and sclerotic disease features, with ongoing sampling until thematic saturation.<\/jats:p><\/jats:sec>Main Outcomes<\/jats:title>HRQOL domains and codes from patient perspectives of living with cutaneous chronic GVHD were identified by inductive analysis of semistructured interviews. Smith salience index (Smith S) score, a measure of saliency for each list term, was calculated from free-listing terms from deidentified patient interviews.<\/jats:p><\/jats:sec>Results<\/jats:title>A total of 31 adults with cutaneous chronic GVHD (median [IQR] age, 61.1 [52.9-68.7] years) participated in interviews; 17 participants (54.8%) were male and 14 (45.2%) were female. Nine participants (29.0%) had epidermal, 13 (41.9%) sclerotic, and 9 (29.0%) a combination of disease types. The study identified 40 codes of importance grouped within 5 HRQOL domains: skin changes and symptoms, social functioning, psychological and emotional functioning, physical functioning, and general health perceptions. The most frequent symptoms were dry skin (n\u2009=\u200920 [65%]), tight skin (n\u2009=\u200919 [61%]), itch (n\u2009=\u200915 [48%]), and discoloration (n\u2009=\u200914 [45%]), which were seen in all disease subtypes. Impairment in social functioning was noted by all participants. Psychological and emotional functioning, including frustration (Smith S score, 0.32) and worry or concern (Smith S score, 0.12), and symptoms including discomfort (Smith S score, 0.20) were the most salient to patients. Individual and environmental factors, such as social comparison, illness comparison with cancer, anatomic location of disease involvement, and disease duration, affected the relationship between skin changes and symptoms and downstream functioning and general health perceptions.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>This qualitative analysis demonstrated the direct relationship between cutaneous chronic GVHD and HRQOL domains and identified codes not represented in existing GVHD- and dermatology-specific patient-reported outcome measures. These results can guide patient-reported outcome development and instrument selection for clinical trials and improve clinical decision-making.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamadermatol.2024.5380","type":"journal-article","created":{"date-parts":[[2025,1,2]],"date-time":"2025-01-02T16:01:23Z","timestamp":1735833683000},"page":"281","source":"Crossref","is-referenced-by-count":2,"title":["Outcomes of Importance to Patients Living With Cutaneous Chronic Graft-vs-Host Disease"],"prefix":"10.1001","volume":"161","author":[{"given":"Emily","family":"Baumrin","sequence":"first","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter F.","family":"Cronholm","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia"},{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew D.","family":"Kearney","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia"},{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mlka","family":"Mengesha","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura G.","family":"Cesar","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shimrit","family":"Keddem","sequence":"additional","affiliation":[{"name":"Department of Family Medicine and Community Health, University of Pennsylvania, Philadelphia"},{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marilyn M.","family":"Schapira","sequence":"additional","affiliation":[{"name":"Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia"},{"name":"Division of General Internal Medicine, University of Pennsylvania, Philadelphia"},{"name":"Center for Health Equity Research and Promotion, Philadelphia VA Medical Center, Philadelphia, Pennsylvania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, Washington"},{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alison W.","family":"Loren","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Department of Medicine, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel M.","family":"Gelfand","sequence":"additional","affiliation":[{"name":"Department of Dermatology, University of Pennsylvania, Philadelphia"},{"name":"Department of Biostatistics, Epidemiology, and Informatics, University of Pennsylvania, Philadelphia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"10","reference":[{"issue":"16","key":"doi240064r1","doi-asserted-by":"publisher","first-page":"2230","DOI":"10.1200\/JCO.2010.33.7212","article-title":"Long-term survival and late deaths after allogeneic hematopoietic cell transplantation.","volume":"29","author":"Wingard","year":"2011","journal-title":"J Clin Oncol"},{"issue":"9","key":"doi240064r2","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-14-0586","article-title":"Impact of chronic graft-versus-host disease on late relapse and survival on 7,489 patients after myeloablative allogeneic hematopoietic cell transplantation for leukemia.","volume":"21","author":"Boyiadzis","year":"2015","journal-title":"Clin Cancer Res"},{"issue":"20","key":"doi240064r3","doi-asserted-by":"publisher","first-page":"4278","DOI":"10.1182\/bloodadvances.2021004941","article-title":"Nonrelapse mortality among patients diagnosed with chronic GVHD: an updated analysis from the Chronic GVHD Consortium.","volume":"5","author":"DeFilipp","year":"2021","journal-title":"Blood Adv"},{"issue":"10","key":"doi240064r4","doi-asserted-by":"publisher","first-page":"3784","DOI":"10.1182\/blood-2007-03-082933","article-title":"Late mortality after allogeneic hematopoietic cell transplantation and functional status of long-term survivors: report from the Bone Marrow Transplant Survivor study.","volume":"110","author":"Bhatia","year":"2007","journal-title":"Blood"},{"issue":"1","key":"doi240064r5","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1056\/NEJM199907013410103","article-title":"Long-term survival and late deaths after allogeneic bone marrow transplantation.","volume":"341","author":"Soci\u00e9","year":"1999","journal-title":"N Engl J Med"},{"issue":"2","key":"doi240064r6","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1182\/blood-2002-01-0011","article-title":"Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.","volume":"100","author":"Flowers","year":"2002","journal-title":"Blood"},{"issue":"13","key":"doi240064r7","doi-asserted-by":"publisher","first-page":"2545","DOI":"10.1182\/blood-2012-04-424135","article-title":"Correlation between NIH composite skin score, patient-reported skin score, and outcome: results from the Chronic GVHD Consortium.","volume":"120","author":"Jacobsohn","year":"2012","journal-title":"Blood"},{"issue":"3","key":"doi240064r8","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.bbmt.2017.10.042","article-title":"Success of immunosuppressive treatments in patients with chronic graft-versus-host disease.","volume":"24","author":"Lee","year":"2018","journal-title":"Biol Blood Marrow Transplant"},{"issue":"22","key":"doi240064r9","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1182\/blood.2021012021","article-title":"Belumosudil for chronic graft-versus-host disease after 2 or more prior lines of therapy: the ROCKstar study.","volume":"138","author":"Cutler","year":"2021","journal-title":"Blood"},{"issue":"3","key":"doi240064r10","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease.","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"doi240064r11","doi-asserted-by":"publisher","first-page":"2243","DOI":"10.1182\/blood-2017-07-793786","article-title":"Ibrutinib for chronic graft-versus-host disease after failure of prior therapy.","volume":"130","author":"Miklos","year":"2017","journal-title":"Blood"},{"issue":"5","key":"doi240064r12","doi-asserted-by":"publisher","first-page":"599","DOI":"10.6004\/jnccn.2020.0021","article-title":"Hematopoietic cell transplantation, version 2.2020, NCCN Clinical Practice Guidelines in Oncology.","volume":"18","author":"Saad","year":"2020","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"doi240064r13","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease I: the 2014 Diagnosis and Staging Working Group report.","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"doi240064r14","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1016\/j.bbmt.2017.06.011","article-title":"Quality of life after allogeneic hematopoietic cell transplantation according to affected organ and severity of chronic graft-versus-host disease.","volume":"23","author":"Kurosawa","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"doi240064r15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1001\/jama.1995.03520250075037","article-title":"Linking clinical variables with health-related quality of life: a conceptual model of patient outcomes.","volume":"273","author":"Wilson","year":"1995","journal-title":"JAMA"},{"issue":"4","key":"doi240064r16","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamadermatol.2023.6277","article-title":"Patient-reported outcomes and mortality in cutaneous chronic graft-vs-host disease.","volume":"160","author":"Baumrin","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"6","key":"doi240064r17","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.bbmt.2015.02.025","article-title":"Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease IV: the 2014 Response Criteria Working Group report.","volume":"21","author":"Lee","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"10","key":"doi240064r18","doi-asserted-by":"publisher","first-page":"1236","DOI":"10.1001\/jamadermatol.2021.3341","article-title":"Patient-reported outcome measures as complementary information to clinician-reported outcome measures in patients with psoriasis.","volume":"157","author":"Barbieri","year":"2021","journal-title":"JAMA Dermatol"},{"issue":"11","key":"doi240064r19","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1002\/acr.20276","article-title":"Patient-reported outcome assessment in vasculitis may provide important data and a unique perspective.","volume":"62","author":"Herlyn","year":"2010","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"doi240064r20","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1001\/jamadermatol.2023.2008","article-title":"Understanding discordant perceptions of disease severity between physicians and patients with eczema and psoriasis using structural equation modeling.","volume":"159","author":"Long","year":"2023","journal-title":"JAMA Dermatol"},{"key":"doi240064r22","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2021.687675","article-title":"\u201cThis graft-vs-host disease determines my life. that\u2019s it:\u201d a qualitative analysis of the experiences and needs of allogenic hematopoietic stem cells transplantation survivors in Germany.","volume":"9","author":"Parisek","year":"2021","journal-title":"Front Public Health"},{"issue":"1","key":"doi240064r23","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12955-020-01651-2","article-title":"\u201cIs this the GVHD?\u201d a qualitative exploration of quality of life issues in individuals with graft-versus-host disease following allogeneic stem cell transplant and their experiences of a specialist multidisciplinary bone marrow transplant service.","volume":"19","author":"de Vere Hunt","year":"2021","journal-title":"Health Qual Life Outcomes"},{"issue":"5","key":"doi240064r24","doi-asserted-by":"publisher","first-page":"e113","DOI":"10.1016\/j.bbmt.2020.01.022","article-title":"Systematic review of patient-reported outcome measures in graft-versus-host disease.","volume":"26","author":"Kilgour","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"6","key":"doi240064r26","doi-asserted-by":"publisher","first-page":"S385","DOI":"10.1093\/geronb\/63.6.S385","article-title":"Using freelisting to identify, assess, and characterize age differences in shared cultural domains.","volume":"63","author":"Schrauf","year":"2008","journal-title":"J Gerontol B Psychol Sci Soc Sci"},{"key":"doi240064r27","doi-asserted-by":"publisher","first-page":"17","DOI":"10.2147\/PROM.S144992","article-title":"Health-related quality of life in ANCA-associated vasculitis and item generation for a disease-specific patient-reported outcome measure.","volume":"9","author":"Robson","year":"2018","journal-title":"Patient Relat Outcome Meas"},{"issue":"6","key":"doi240064r28","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups.","volume":"19","author":"Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"3","key":"doi240064r30","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1586\/erp.10.30","article-title":"Assessing and demonstrating data saturation in qualitative inquiry supporting patient-reported outcomes research.","volume":"10","author":"Kerr","year":"2010","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"doi240064r31","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1177\/0894439312455312","article-title":"Mode effects in free-list elicitation: comparing oral, written, and web-based data collection.","volume":"31","author":"Gravlee","year":"2013","journal-title":"Soc Sci Comput Rev"},{"key":"doi240064r32","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1177\/0081175012465967","article-title":"Telephone versus face-to-face interviews: mode effect on semi-structured interviews with children.","volume":"43","author":"Vogl","year":"2013","journal-title":"Sociol Methodol"},{"issue":"3","key":"doi240064r33","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1111\/j.1365-2230.1994.tb01167.x","article-title":"Dermatology Life Quality Index (DLQI)\u2014a simple practical measure for routine clinical use.","volume":"19","author":"Finlay","year":"1994","journal-title":"Clin Exp Dermatol"},{"issue":"8","key":"doi240064r34","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1136\/annrheumdis-2016-210534","article-title":"Development and validation of a patient-reported outcome instrument for skin involvement in patients with systemic sclerosis.","volume":"76","author":"Man","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"doi240064r35","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1001\/archderm.1997.03890470111018","article-title":"Improved discriminative and evaluative capability of a refined version of Skindex, a quality-of-life instrument for patients with skin diseases.","volume":"133","author":"Chren","year":"1997","journal-title":"Arch Dermatol"},{"key":"doi240064r36","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1177\/1094428107300228","article-title":"On measuring individual knowledge in organizations.","volume":"10","author":"Borgatti","year":"2007","journal-title":"Organ Res Methods"},{"issue":"4","key":"doi240064r38","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.bbmt.2019.10.019","article-title":"Disability related to chronic graft-versus-host disease.","volume":"26","author":"Hamilton","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"doi240064r39","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1001\/jamadermatol.2022.6624","article-title":"Prognostic value of cutaneous disease severity estimates on survival outcomes in patients with chronic graft-vs-host disease.","volume":"159","author":"Baumrin","year":"2023","journal-title":"JAMA Dermatol"},{"issue":"8","key":"doi240064r40","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1053\/bbmt.2002.v8.pm12234170","article-title":"Development and validation of a scale to measure symptoms of chronic graft-versus-host disease.","volume":"8","author":"Lee","year":"2002","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"doi240064r41","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.bbmt.2019.11.020","article-title":"Reliability and validity of the Modified 7-day Lee Chronic Graft-versus-Host Disease Symptom Scale.","volume":"26","author":"Teh","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"doi240064r42","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1111\/1523-1747.ep12365600","article-title":"Skindex, a quality-of-life measure for patients with skin disease: reliability, validity, and responsiveness.","volume":"107","author":"Chren","year":"1996","journal-title":"J Invest Dermatol"},{"issue":"4","key":"doi240064r43","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1001\/jamadermatol.2023.6245","article-title":"Identifying core outcome domains in chronic skin disease using the best-worst scaling method.","volume":"160","author":"Shields","year":"2024","journal-title":"JAMA Dermatol"},{"issue":"3","key":"doi240064r44","doi-asserted-by":"publisher","first-page":"e194","DOI":"10.1111\/bjd.16099","article-title":"Risk of depression among patients with acne in the UK: a population-based cohort study.","volume":"178","author":"Vallerand","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"doi240064r45","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/jamadermatol.2019.4857","article-title":"Quality of life in patients with skin of color and chronic graft-vs-host disease.","volume":"156","author":"Smith","year":"2020","journal-title":"JAMA Dermatol"},{"key":"doi240064r25","first-page":"115","volume-title":"Enhanced Ethnographic Methods: Audiovisual Techniques, Focused Group Interviews, and Elicitation Techniques","author":"Borgatti","year":"1999"},{"key":"doi240064r29","volume-title":"Qualitative Research and Evaluation Methods","author":"Patton","year":"2002"},{"key":"doi240064r37","first-page":"549","volume-title":"The Handbook of Methods in Cultural Anthropology","author":"Handweker","year":"1998"},{"key":"doi240064r21","unstructured":"US Department of Health and Human Services. Guidance for industry: patient-reported outcome measures: use in medical product development to support labelling claims. December 2009. Accessed January 11, 2024. https:\/\/www.fda.gov\/media\/77832\/download"}],"container-title":["JAMA Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/articlepdf\/2828275\/jamadermatology_baumrin_2025_oi_240064_1741115875.42864.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,19]],"date-time":"2025-03-19T15:56:08Z","timestamp":1742399768000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamadermatology\/fullarticle\/2828275"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":45,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamadermatol.2024.5380","relation":{},"ISSN":["2168-6068"],"issn-type":[{"value":"2168-6068","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3,1]]}}}